Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 20380564.
- Also identified by DOI 10.1086/652149.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We assessed the risk of clinically significant drug interactions in patients receiving antiretrovirals, and their recognition by physicians. Clinically significant drug interactions were recorded in 27% of 159 patients, with 15% of interactions potentially lowering antiretroviral concentrations. Risk of clinically significant drug interactions was significantly related to receipt of protease inhibitors. Only 36% of clinically significant drug interactions were correctly identified by physicians.
Medical subject headings
- Anti-HIV Agents
- Antiretroviral Therapy, Highly Active
- HIV Infections
- Risk Assessment